L3.3 Rheumatoid Arthritis & psoriasis Flashcards
1
Q
What is central and peripheral tolerance?
A
Self-reacting usually prevented by central & peripheral tolerance
- Central = regulating the type of T cell produced via CD8+ immune surveillance
- Peripheral = involves a series of suppressions on T and B cells
2
Q
What is autoimmunity and how does it occur?
A
immune system unable to discriminate b/w non-self & self
- Occurs via:
- Breakdown of tolerance
- Post-translational modifications (env + epigenetics + susceptible genes)
Hard to remove AI disease if memory T & B cells are involved
3
Q
Into what cytokines do CD4 cells differentiate into?
A
- Th17 produces th17 cytokines
- Brings neutrophils to injury sites
4
Q
What can th17 cells be induced into?
A
Could be induced into:
- Th17 - from TGF-B & IL6
- Produces IL17
- Th1 - from T-bet
- Produces IF-γ
5
Q
Features of R.A
A
- Unknown etiology (origins)
- Females > males (3:1)
- Diagnosis:
- Morning stiffness > one hour
- Arthritis in 3 or more joints
- Disease symmetrical
- Radiological changes
- Smoking is the main risk factor
6
Q
Mechanism of RA
A
- Synovial membrane (synovitis)
- Inflammation not resolved
- Tissue hyperplasia, inflammatory cells invade & pannus formation
- Pannus = benign tumour
- Pannus self-irritates → grows → recruits more inflammatory cells
- Neoangiogenesis → to sustain inflammatory cells to site
- Generalise vasculitis → ↑risks of heart attack
- Pro-inflammatory cytokines permeate bones → cartilage/bone degeneration
- GM-CSF irritate macrophage → promotes further breakdown of joint tissues
- May also affect brain functions (depression)
7
Q
Drugs targeting RA
A
- CCR1 Antagonists
- p38 inhibitors
- ICE inhibitors
- NSAIDs
8
Q
CCR1 antagonists
A
- Block chemokine receptors that assist leukocyte infiltration into tissue
- But fairly non-specific - problems with infection
9
Q
p38 inhibitors
A
- P38 is one of the main signalling molecules in inflammation cascades
- Ass with lots of problems e.g. lung infections
10
Q
ICE inhibitors
A
- ICE is a converting enzyme that converts many molecules
11
Q
NSAIDs
A
- Classically target PGE2
12
Q
Limitations of GC
A
- Systemic SE with long term admin
- Represses cartilage and bone formation
- Accelerates joint degeneration
13
Q
Limitations of DMARDs
A
- “Disease modifying anti-rheumatic agents
- Immunosuppressant of T-cells
- ↑side effects & ↓effectiveness
- Delayed onset on action
14
Q
Changes in treatment
A
- Earlier use of aggressive treatment
- Biological + combination therapy → allows earlier/permanent remission
15
Q
2 examples of Anti-TNF biologicals
A
- Etanercept & Infliximab